Historically, Otonomy, Inc. was dedicated to the development of innovative therapeutics for neurotology. Otonomy’s Board of Directors seeks, as a next step in its efforts to maximize shareholder value, to effect Otonomy’s dissolution, including the monetization of Otonomy’s remaining holdings and other assets and the deregistration of Otonomy’s common stock with the Securities and Exchange Commission (“SEC”). In furtherance of these efforts, the Board is presenting the Dissolution Proposal for approval by Otonomy’s stockholders at a Special Meeting of Stockholders to be held March 24, 2023. Details regarding the Dissolution Proposal and Special Meeting can be found in a proxy statement filed with the SEC on February 13, 2023 that is available on the SEC Filings page of this website.
